Susquehanna International Group, LLP Morpho Sys Ag Transaction History

Susquehanna International Group, LLP

  • $560 Billion
  • Q3 2024

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$4.55 - $9.9 $1.35 Million - $2.93 Million
295,618 Added 1435.46%
316,212 $3.13 Million
Q3 2023

Nov 14, 2023
BUY
$6.72 - $8.6 $19,360 - $24,776
2,881 Added 16.26%
20,594 $138,000
Q2 2023

Aug 11, 2023
BUY
$3.95 - $7.74 $69,966 - $137,098
17,713 New
17,713 $132,000
Q4 2022

Feb 14, 2023
BUY
$3.21 - $5.74 $34,440 - $61,584
10,729 New
10,729 $38,000
Q1 2022

May 16, 2022
SELL
$5.87 - $9.73 $146,462 - $242,773
-24,951 Closed
0 $0
Q4 2021

Feb 14, 2022
BUY
$9.08 - $12.45 $226,555 - $310,639
24,951 New
24,951 $235,000

Others Institutions Holding MOR

# of Institutions
13
Shares Held
1.8M
Call Options Held
0
Put Options Held
14.7K
View Full List

About MorphoSys AG

MOR Quotes by TradingView
  • Ticker MOR
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 136,614,000
  • Description
  • MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...
More about MOR
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email